Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer
-
Published:2023-11
Issue:
Volume:
Page:
-
ISSN:1525-7304
-
Container-title:Clinical Lung Cancer
-
language:en
-
Short-container-title:Clinical Lung Cancer
Author:
Riudavets Mariona, Auclin Edouard, Mosteiro Miguel, Dempsey Naomi, Majem Margarita, Prelaj Arsela, López-Castro Rafael, Bosch-Barrera Joaquim, Pilotto Sara, Escalera Elena, Tagliamento Marco, Mosquera Joaquin, Zalcman Gérard, Aboubakar Nana Frank, Ponce Santiago, Albarrán-Artahona VíctorORCID, Dal Maso Alessandro, Spotti Martina, Mielgo Xabier, Mussat Elodie, Reyes Roxana, Benítez Jose-Carlos, Lupinacci Lorena, Duchemann Boris, De Giglio Andrea, Blaquier Juan Bautista, Audigier-Valette Clarisse, Scheffler Matthias, Nadal Ernest, Lopes Gilberto, Signorelli Diego, Garcia-Campelo Rosario, Menis Jessica, Bluthgen Virginia, Campayo Marc, Recondo Gonzalo, Besse Benjamin, Mezquita Laura, Planchard David
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference38 articles.
1. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N Engl J Med,2017 2. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N Engl J Med,2018 3. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer;Antonia;N Engl J Med,2017 4. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial;Faivre-Finn;J Thorac Oncol,2021 5. European Medicines Agency. Durvalumab (Imfinzi), Summary of product characteristics 2018. Available at: https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Accessed: July 27, 2023.
|
|